Welcome to our dedicated page for Prelude Therapeutics SEC filings (Ticker: PRLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company. Through these regulatory documents, investors can review how Prelude describes its business, pipeline, risks, and financial condition as it advances programs such as SMARCA2 and KAT6A degraders, mutant selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms, and mutant CALR-targeted degrader antibody conjugates (DACs).
Key filings include annual reports on Form 10-K, which provide an overview of Prelude’s precision oncology strategy, target selection, collaborations, and risk factors, and quarterly reports on Form 10-Q, which update on operating expenses, cash runway, and development progress. Current reports on Form 8-K disclose material events such as the exclusive option agreement with Incyte for the JAK2V617F program, expanded arrangements with AbCellera Biologics, clinical portfolio reprioritizations, Nasdaq listing compliance updates, and changes in board or executive roles.
Investors interested in ownership and governance can also use SEC filings to track equity financings, non-voting common stock issuances, and other capital structure changes described in transaction-related 8-Ks and registration statements. These documents outline terms of option agreements, securities purchase agreements, and related registration rights for Prelude’s stock.
On Stock Titan, each new PRLD filing is captured from EDGAR and paired with AI-powered summaries that highlight the most relevant points, such as pipeline focus, collaboration economics, cash position commentary, and listing status updates. This helps readers navigate lengthy reports and quickly locate information on topics like JAK2V617F program economics, SMARCA2 and KAT6A development plans, and the impact of strategic decisions on Prelude’s financial profile.
Use this page to access Prelude Therapeutics’ 10-K, 10-Q, 8-K and related filings, along with concise AI explanations that clarify technical disclosures and regulatory language for PRLD stock watchers.
Prelude Therapeutics Incorporated has priced an underwritten equity offering to raise capital for its oncology pipeline and operations. The company agreed to sell 18,018,014 shares of common stock at $4.44 per share and pre-funded warrants to purchase up to 2,252,252 shares at $4.4399 per warrant with a $0.0001 exercise price. Gross proceeds are expected to be about $90.0 million, with estimated net proceeds of approximately $85.5 million after fees and expenses. Prelude plans to use the funds mainly for general corporate purposes, including research, preclinical and clinical development, working capital, and capital expenditures, and currently expects its cash plus these proceeds to fund operations into the second quarter of 2028.
Prelude Therapeutics Incorporated has priced an underwritten equity offering to raise capital for its oncology pipeline and operations. The company agreed to sell 18,018,014 shares of common stock at $4.44 per share and pre-funded warrants to purchase up to 2,252,252 shares at $4.4399 per warrant with a $0.0001 exercise price. Gross proceeds are expected to be about $90.0 million, with estimated net proceeds of approximately $85.5 million after fees and expenses. Prelude plans to use the funds mainly for general corporate purposes, including research, preclinical and clinical development, working capital, and capital expenditures, and currently expects its cash plus these proceeds to fund operations into the second quarter of 2028.
Prelude Therapeutics (PRLD) is offering 18,018,014 shares of common stock and, in lieu of shares to certain investors, 2,252,252 pre‑funded warrants exercisable into one share each. The public offering price is $4.44 per share (pre‑funded warrant price $4.4399). Net proceeds are estimated at approximately $85.5 million, which the company expects to fund operations into the second quarter of 2028 based on preliminary estimates. Certain investment entities affiliated with directors will purchase an aggregate of 2,815,315 shares and 2,252,252 pre‑funded warrants at the public offering price. The pre‑funded warrants have an exercise price of $0.0001, contain a 4.99% beneficial ownership limitation (adjustable to 19.99% with notice), and will not be listed for trading.
Prelude Therapeutics (PRLD) is offering 18,018,014 shares of common stock and, in lieu of shares to certain investors, 2,252,252 pre‑funded warrants exercisable into one share each. The public offering price is $4.44 per share (pre‑funded warrant price $4.4399). Net proceeds are estimated at approximately $85.5 million, which the company expects to fund operations into the second quarter of 2028 based on preliminary estimates. Certain investment entities affiliated with directors will purchase an aggregate of 2,815,315 shares and 2,252,252 pre‑funded warrants at the public offering price. The pre‑funded warrants have an exercise price of $0.0001, contain a 4.99% beneficial ownership limitation (adjustable to 19.99% with notice), and will not be listed for trading.
Prelude Therapeutics Incorporated furnished an update on its precision oncology pipeline and cash position, highlighted by new preclinical data for lead candidate PRT13722, a first-in-class, orally bioavailable, highly selective KAT6A degrader for HR+/HER2- breast cancer.
At the AACR Annual Meeting 2026, PRT13722 showed potent preclinical antitumor activity, including complete responses in multiple breast cancer models, and signs of a more favorable hematologic safety profile than dual KAT6A/B inhibitors. An IND filing for PRT13722 is planned for mid‑2026, with a Phase 1 trial expected to begin in the second half of 2026.
The company also highlighted PRT12396, a JAK2V617F‑mutant selective JH2 inhibitor now in Phase 1 for myeloproliferative neoplasms, and an early mCALR‑targeted degrader antibody conjugate program. Prelude reported $106 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025, which it expects to fund operations into the second quarter of 2027.
Prelude Therapeutics Incorporated furnished an update on its precision oncology pipeline and cash position, highlighted by new preclinical data for lead candidate PRT13722, a first-in-class, orally bioavailable, highly selective KAT6A degrader for HR+/HER2- breast cancer.
At the AACR Annual Meeting 2026, PRT13722 showed potent preclinical antitumor activity, including complete responses in multiple breast cancer models, and signs of a more favorable hematologic safety profile than dual KAT6A/B inhibitors. An IND filing for PRT13722 is planned for mid‑2026, with a Phase 1 trial expected to begin in the second half of 2026.
The company also highlighted PRT12396, a JAK2V617F‑mutant selective JH2 inhibitor now in Phase 1 for myeloproliferative neoplasms, and an early mCALR‑targeted degrader antibody conjugate program. Prelude reported $106 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025, which it expects to fund operations into the second quarter of 2027.
Prelude Therapeutics Inc filed an initial Form 3 for Chief Medical Officer Charles Q. Morris. This filing identifies him as an officer and subject to insider reporting rules but, in this excerpt, shows no reported transactions or holdings data.
Prelude Therapeutics Incorporated appointed Dr. Charles Morris as Executive Vice President and Chief Medical Officer, effective April 20, 2026. He brings over 30 years of oncology drug development experience, including prior CMO roles at Lava Therapeutics, Celyad Oncology, Radius Health, ImmunoGen and Allos Therapeutics.
Under his employment agreement, Dr. Morris will receive a $535,000 initial annual base salary, a discretionary target bonus up to 40% of base salary, and an option to purchase 450,000 shares of common stock vesting over four years. If his employment is terminated without Cause or he resigns for Good Reason, he is eligible for nine months of salary and healthcare premiums, increasing to 12 months of salary and healthcare, 100% of his target bonus, and full vesting of equity awards if such termination occurs within 12 months after a Change in Control.
The company describes itself as a clinical-stage precision oncology firm with programs in KAT6A degraders and JAK2V617F mutant-selective inhibitors, aiming to move two lead programs into clinical development in 2026.
Prelude Therapeutics Inc executive Sean P. Brusky, Chief Business Officer, filed an initial ownership report showing his current equity position in the company. He holds stock options over 300,000, 175,000 and 275,000 shares of common stock, each with a stated exercise price of $0.0000 per share and expirations in 2034, 2035 and 2036.
He also directly owns 100,000 shares of common stock. Footnotes explain these options were granted on May 1, 2024, February 4, 2025 and February 4, 2026 under the 2020 Equity Incentive Plan, with 25% vesting after one year and the remainder vesting monthly over the following three years, subject to his continued service.
Prelude Therapeutics Incorporated filed a current report describing an update to its at-the-market stock sale program. The company previously entered into an Open Market Sale agreement with Jefferies LLC that allows it to sell up to $75.0 million of common stock over time.
On March 12, 2026, Prelude filed a prospectus supplement under its existing shelf registration statement. This supplement permits the company to offer and sell additional shares of common stock having an aggregate offering price of up to $25.0 million from time to time through Jefferies acting as sales agent. A legal opinion from Morgan, Lewis & Bockius LLP regarding these shares is included as an exhibit.
Prelude Therapeutics Incorporated is offering, pursuant to an existing Sales Agreement with Jefferies LLC, common stock having an aggregate offering price of up to $25.0 million on an at-the-market basis.
The sales will be made through Jefferies acting as agent under an existing agreement that could permit sales of up to $75.0 million of common stock in total under prior arrangements. Jefferies’ compensation is up to 3.0% of aggregate gross proceeds, and sales may occur from time to time at market prices. The summary figures use a share count of 62,953,628 shares outstanding as of December 31, 2025 as disclosed in the prospectus supplement.
Prelude Therapeutics filed its annual report detailing a precision oncology pipeline and several major collaborations. Lead JAK2V617F inhibitor PRT12396 has FDA IND clearance, with a Phase 1 study planned for the second quarter of 2026 and an exclusive option deal with Incyte that includes a $100 million option exercise price and up to $910 million in potential cash payments, of which $60 million has already been received. The company is advancing a selective KAT6A degrader toward an IND in mid‑2026 and has expanded a multi‑program degrader antibody conjugate collaboration with AbCellera that delivered $12.5 million in upfront payments plus future milestones and royalties. Prelude paused clinical development of its SMARCA2 degrader program to prioritize resources, while highlighting a broad early‑stage degrader and precision ADC platform and a substantial global patent estate.
Prelude Therapeutics reported 2025 results showing reduced spending and a smaller loss while advancing its oncology pipeline. Revenue was $12.1 million versus $7.0 million in 2024, largely from collaborations. Research and development expenses fell to $94.3 million from $118.0 million, and general and administrative expenses dropped to $22.4 million from $28.7 million, reflecting lower stock-based compensation and discontinued trials.
Net loss narrowed to $99.5 million, or $1.29 per share, compared with $127.2 million, or $1.68 per share, a year earlier. Cash, cash equivalents, restricted cash and marketable securities totaled $106.4 million as of December 31, 2025, which the company expects will fund operations into the second quarter of 2027.
On the pipeline side, the FDA cleared the IND for lead JAK2V617F inhibitor PRT12396, with a Phase 1 trial in high-risk polycythemia vera and myelofibrosis anticipated to start in the second quarter of 2026. KAT6A degrader PRT13722 is in IND-enabling studies, with an IND filing planned for mid-2026 and a Phase 1 study expected in the second half of 2026. Prelude also expanded its degrader antibody conjugate collaboration with AbCellera and highlighted early mCALR-targeted DAC work, while maintaining an exclusive option agreement with Incyte for the JAK2V617F program.